1.

Novel cholesterol biosynthesis inhibitors targeting the human lanosterol 14[alpha]-demethylase (CYP51).

Design, synthesis and SAR of LK-935 derivatives has been described and classification to subclasses according to sterol profile. Activity of novel original hypolipemics and comparision of activity with statins was described.

COBISS.SI-ID: 2235249

2.

The Sterolgene v0 cDNA microarray : a systemic approach to studies of cholesterol homeostasis and drug metabolism.

Construction and use of original low-density DNA microarray has been described and comparision with commercial high-density microarrays with correspondence to quantitative response on gene expression on cholesterol homeostasis.

COBISS.SI-ID: 23814361

3.

Drug-interaction potential of LK-935, the novel non-statin type cholesterol lowering agent

Drug-interaction potential of LK-935, the novel non-statin type cholesterol lowering agent hase been investigated and comparision to statins made on primary hapatocytes.

COBISS.SI-ID: 24945625

4.

Towards identification of gene interaction networks of human cholesterol biosynthesis.

The manuscript describes construction of gene regulatory networks with the Bayesian approach, on the basis of transcriptome results from human primary hepatocytes treated with hypolipidemic drugs.

COBISS.SI-ID: 24460249

5.

Expression of microsomal lanosterol 14alpha-demethylase (CYP51) in an engineered soluble monomeric form.

We have prepared a soluble monomeric form of the bovine cytochrome P450 lanosterol 14a-demethylase (CYP51). Activity of bCYP51-d1 is similar to that of the recombinant human CYP51.

COBISS.SI-ID: 24225241